Effect of exisulind, docetaxel, and the combination on the number of athymic rats with metastases from orthotopic A549 tumors (second experiment)
| Treatment | Dose and schedule | Mean survival days (P, log-rank) | # rats with mets/# treated (P, Fisher’s exact test) |
|---|---|---|---|
| Control | 35.7 days | 15/15 | |
| Exisulind | 25 mg/kg daily | 36 days | 12/12 |
| (P = 0.76) | (P = 1.0) | ||
| Exisulind | 50 mg/kg daily | 41.08 days | 11/12 |
| (P = 0.31) | (P = 0.41) | ||
| Docetaxel | 2.5 mg/kg/wk (6×) | 34.5 days | 12/12 |
| (P = 0.66) | (P = 1.0) | ||
| Docetaxel | 5 mg/kg/wk (6×) | 43.58 days | 9/12 |
| (P = 0.17) | (P = 0.06) | ||
| Exisulind | 25 mg/kg daily | 35.5 days | 12/12 |
| Docetaxel | 2.5 mg/kg/wk (6×) | (P = 0.68) | (P = 1.0) |
| Exisulind | 25 mg/kg daily | 49.33 days | 8/12 |
| Docetaxel | 5 mg/kg/wk (6×) | (P = 0.04) | (P = 0.02) |
| Exisulind | 50 mg/kg daily | 36 days | 11/12 |
| Docetaxel | 2.5 mg/kg/wk (6×) | (P = 0.31) | (P = 0.41) |
| Exisulind | 50 mg/kg daily | 63.17 days | 2/12 |
| Docetaxel | 5 mg/kg/wk (6×) | (P < 0.0004) | (P < 0.0001) |
| Exisulind | 50 mg/kg daily | 65.17 days | 1/12 |
| Docetaxela | 5 mg/kg/wk (3×) | (P < 0.0001) | (P < 0.0001) |
| 2.5 mg/kg/wk (3×) |
a Docetaxel was administered at 5 mg/kg/wk for the weeks 1–3 and at the lower dose of 2.5 mg/kg/wk for weeks 4–6.